$QGEN

QIAGEN (QGEN) said the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel in August 2026, expanding bloodstream infection diagnostics with one-hour detection of multiple pathogens and AMR markers from positive blood cultures. The article links the clearance to QIAstat-Dx growth and notes Q2 2026 results slightly beat outlook and reaffirmed full-year guidance, with 2029 revenue and earnings forecasts cited.

QIAGEN N.V. (QGEN) shares fell about 6% after hours after it cut fiscal 2026 guidance. The company now expects adjusted diluted EPS of at least $2.43 at constant exchange rates, down from $2.50, and net sales growth of 1-2% versus at least 5%. It cited weaker QuantiFERON TB test demand, including lower U.S. immigration testing. Q1 net sales were $492M and adjusted EPS $0.54 CER.

Qiagen (QGEN) reported Q2 2026 net sales of $535 million, flat vs a guidance call for about a 2% decline, and adjusted diluted EPS of $0.62, ahead of outlook, according to the company. Growth pillars rose 5% CER, but diagnostics and PCR sales fell and margins slipped to 29.4% from 29.9%. Full-year relies on new launches and easier comparisons.

Qiagen (QGEN) reported Q2 2026 adjusted diluted EPS of $0.62 at constant exchange rates, above its outlook of at least $0.60. Growth pillars rose 5% at CER, with Sample Technologies up 9% CER and QIAcuity delivering double-digit growth. Adjusted operating income was $157 million (29.4% margin). Operating cash flow was $301 million for 6 months, and the company increased its 2026 dividend 40% to $0.35.

German stocks rose as the DAX hit a record 26,521.50 despite July CPI accelerating to 2.8% y/y (from 2.3% in June), per Destatis. EU HICP also rose to 2.8%. Siemens Energy (+4%), Infineon (+3%) and Rheinmetall (+2.1%) gained. Indus Holding rallied after raising 2026 guidance; Brenntag, E.ON and others reported results.

Qiagen (QGEN) reported total revenue of $535.04 million for the quarter ended June 2026, up 0.3%. International segment revenue included $72 million from Asia Pacific, Japan and Rest of World (13.5%), and $178 million from Europe, Middle East and Africa (33.3%). Analysts projected $541.05 million total revenue for the current fiscal quarter.

QIAGEN reported Q2 genomics and NGS sales up 2% at constant exchange rates, with QIAGEN Digital Insights growing single digits and universal NGS panel consumables for third-party sequencers rising over 20%. Adjusted operating income fell 2% to $157M, margin 29.4%. Operating cash flow was $301M for 1H. QGEN reaffirmed FY sales growth of ~1% to 2% and adjusted diluted EPS at least $2.43.

Qiagen (QGEN) said its 2026 AGM approved amendments to its Articles of Association, allowing a reverse stock split, changes to par value, and a potential shareholder repayment of up to US$200 million. The article also cites Q2 results of US$535.04 million in sales and US$103.4 million net income, and notes analyst forecasts for 2029 revenue around US$2.6 billion.

QIAGEN reported Q2 2026 net sales of $535 million, flat year over year and ahead of guidance for a decline, with growth from Sample technologies, QIAcuity and QIAGEN Digital Insights offsetting weaker instrument demand. Adjusted diluted EPS was $0.62 versus outlook of at least $0.60, with 29.4% adjusted operating margin and $301 million operating cash flow in H1. The company reaffirmed full-year 2026 guidance of 1–2% net sales growth and adjusted diluted EPS of at least $2.43.

Germany’s DAX rose 0.64% to 26,333.28 as investors weighed earnings and oil moves. Brent futures neared $83 amid uncertainty about reopening the Strait of Hormuz. Company moves included Scout24 up 5%, SAP up 3.75%, Infineon up 3%, and Daimler Truck Holding down about 4.2%. Munich Re fell 2.7% and Allianz slipped after earnings.